HomeAllClinical Handbook of Psychotropic Drugs for Children and Adolescents
Skip to product information
1 of 1

Clinical Handbook of Psychotropic Drugs for Children and Adolescents

spiral_boundNovember 1, 2018
Regular price $480.22 USD
Regular price Sale price $480.22 USD
Sale Sold out
Shipping calculated at checkout.
Free Shipping
Secure Checkout
Quality Guaranteed
New In Stock
ISBN-13: 9780889375505 ISBN-10: 088937550X
Publisher
HOGREFE (VORM. VERLAG HANS HUBER )
Binding
spiral_bound
Published
November 1, 2018
Weight
2.8 lbs
Dimensions
27.30×2.50×22.90 cm

About this book

Clinical Handbook of Psychotropic Drugs for Children and Adolescents by Elbe, Dean. spiral_bound edition. ISBN: 9780889375505.

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals. • • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options • • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drug • • Potential interactions and side effects summarized in comparison charts • • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek • • Clearly written patient and caregiver information sheets for download as printable PDF files This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition: • • Drugs for ADHD thoroughly revised and updated • • Antipsychotics with many changes and additions, including fully revised lab tests/monitoring • • Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations • • Hypnotics completely revised • • Mood stabilizers fully revised and a new toxicity comparison table added • • Drugs of abuse and treatment of substance use disorder comprehensively revised • • New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use, and irritability of autism • • New agents include: TGAs N-arylpiperazine (brexpiprazole) and phenylpiperazine (cariprazine), hypnotics orexin receptor antagonist (hypnotic suvorexant) and selective melatonin agonist (tasimelteon), antidepressant bisarylsulfanyl amine (vortioxetine) • • New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR, Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Som-Pam, Tegretol (liquid), Trintellix, Versacolz, Vraylar, Vyvanse, Zelapar, Zenzedi